 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Amoebics does not plan to take its products to the market itself. Rather it plans to partner with appropriate major pharmaceutical companies. The timing of this partnering will be dependent upon the markets being addressed and the quality of results obtained.
This commercial strategy is underpinned by the Company’s strong intellectual property position covering the use of amoeba derived proteins for the treatment of microbial disease. |
|
|
|
|
|
| ©
AMOEBICS Ltd. 2004. All rights reserved. |
 |
|
|
|
